Cargando…
Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
BACKGROUND: Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or am...
Autores principales: | Liu, Rongrui, Liu, Lianke, Zhao, Chuanhua, Bai, Yuxian, Zheng, Yulong, Zhang, Shu, Li, Ning, Yang, Jianwei, Fan, Qingxia, Wang, Xiuwen, Zeng, Shan, Zhang, Yingjun, Zhang, Weihong, Zhuang, Yulei, Kang, Ning, Jiang, Yingzhi, Sun, Hongmei, Xu, Jianming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540164/ https://www.ncbi.nlm.nih.gov/pubmed/34688250 http://dx.doi.org/10.1186/s12876-021-01982-4 |
Ejemplares similares
-
Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors
por: Liu, Jingrui, et al.
Publicado: (2021) -
A combined immune prognostic index in esophageal squamous cell carcinoma patients treated with anti-PD-1 therapy
por: Ji, Shoujian, et al.
Publicado: (2023) -
A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
por: Zhao, Chuanhua, et al.
Publicado: (2016) -
Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status
por: Zhang, Guochun, et al.
Publicado: (2022) -
Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
por: Xu, Jianming, et al.
Publicado: (2020)